Comparative Pharmacology
Head-to-head clinical analysis: RENFLEXIS versus SIMPONI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENFLEXIS versus SIMPONI.
RENFLEXIS vs SIMPONI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Renflexis (infliximab-abda) is a chimeric monoclonal antibody that binds with high affinity to tumor necrosis factor alpha (TNFα), neutralizing its pro-inflammatory activity. It inhibits TNFα binding to its receptors (TNFR1 and TNFR2), reducing inflammatory cell migration, cytokine production, and tissue damage.
Golimumab is a human monoclonal antibody that binds to and neutralizes tumor necrosis factor alpha (TNF-α), inhibiting its interaction with TNF receptors and thereby reducing inflammatory responses.
5 mg/kg intravenously over at least 2 hours at 0, 2, and 6 weeks, then every 8 weeks.
Simponi (golimumab) is administered subcutaneously. For adult rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: 50 mg once monthly. For ulcerative colitis: 200 mg subcutaneously at week 0, then 100 mg at week 2, then 100 mg every 4 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 18-21 days (mean ~20 days) in patients with rheumatoid arthritis; supports every-8-week dosing interval.
Terminal elimination half-life approximately 12-14 days (mean 12.3 days in rheumatoid arthritis patients). Supports subcutaneous dosing every 2 weeks.
Primarily eliminated via reticuloendothelial system degradation; renal excretion accounts for <1% of dose as unchanged drug; no significant biliary or fecal excretion.
Primarily degraded into small peptides and amino acids via reticuloendothelial system; no significant renal or biliary elimination. Less than 0.1% excreted unchanged in urine.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor